The FDA has approved Tekturna (aliskiren tablets, from Novartis), a once-daily oral medication for the treatment of hypertension as monotherapy or in combination with other antihypertensive agents. In clinical trials, this direct renin inhibitor demonstrated significant blood pressure reductions for a full 24 hours. Tekturna is expected to be available in March 2007 as 150mg and 300mg tablets.

For more information call (888) TEKTURNA or visit